Cancer patients may have an increased risk of developing second primary malignancies after immune checkpoint inhibitor therapy.

A 40-gene expression profile test can improve risk stratification for patients with CSCC, according to researchers.

The Senate has confirmed Dr Jay Bhattacharya as the new director of the NIH and Dr Marty Makary as the new commissioner of the FDA.

Combining savolitinib with osimertinib can reverse osimertinib resistance in patients with advanced, EGFR-mutant NSCLC, data suggest.

ICI-based combinations are the preferred first-line therapy due to their proven superiority over TKI monotherapy, many patients were not receiving them,” the researchers wrote.

The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

We want you to take advantage of everything Cancer Therapy Advisor has to offer. To view unlimited cont ...

Partial nephrectomy provides the best survival rates among treatment options in patients aged 75 years or older with T1-T2 renal cell carcinoma (RCC), according to research presented at the 40th ...

Clinical guidelines should establish clear timelines, and health care systems should prioritize timely treatment initiation and completion,” researchers concluded.

More than 3.8 million US lung cancer deaths were averted during 1970-2022 due to tobacco control, researchers say.

Biomarker testing in advanced NSCLC has increased in recent years, but turnaround time has remained roughly the same, data suggest.

Pembrolizumab and concurrent CRT, followed by pembrolizumab consolidation, provided long-term tumor control in previously untreated, unresectable, stage III NSCLC.